Last updated 2 days ago
A Study to Investigate Progression-Free Survival With Sonrotoclax Plus Obinutuzumab Or Sonrotoclax Plus Rituximab Compared With Venetoclax Plus Rituximab Treatment In Patients With Relapsed and/or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CELESTIAL-RRCLL)
630 patients around the world
Available in Brazil, Argentina, United States
Our company, previously known as BeiGene, is now officially BeOne Medicines. Because some
of our older studies were sponsored under the name BeiGene, you may see both names used
for this study on this website.
BeiGene
12Research sites
630Patients around the world
This study is for people with
Leukemia
Chronic lymphocytic leukemia
Requirements for the patient
From 18 Years
All Gender
Medical requirements
- Confirmed diagnosis of CLL/SLL that meets the International Workshop on Chronic Lymphocytic Leukemia (iwCLL) criteria.Received one or more prior therapies for CLL/SLL.For each line of therapy, participants must have received at least 2 cycles of the therapy.Participants with prior BCL2i exposure are eligible if remission duration was ≥3 years with ≥2 years from last BCL2i intake.Eastern Cooperative Oncology Group (ECOG) Performance Status score of 0, 1, or 2.Adequate organ function.
- Known active prolymphocytic leukemia or currently suspected Richter's transformation.Prior autologous stem cell transplantation or chimeric antigen receptor T-cell therapy within 3 months before first dose of study drug.Prior allogeneic stem cell transplant with active graft-versus-host disease (GVHD), requiring immunosuppressive drugs for treatment of GVHD, or have taken calcineurin inhibitors within 4 weeks prior to consent.Known central nervous system involvement by CLL/SLL.Severe or debilitating pulmonary disease.Clinically significant cardiovascular disease.
Sites
CETUS Hospital Dia Oncologia - Belo Horizonte
Recruiting
Hospital de Clínicas - Universidade Estadual de Campinas - UNICAMP
Recruiting
Hospital Erasto Gaertner
Recruiting
Complexo Hospitalar de Niterói - CHN
Recruiting
Irmandade da Santa Casa de Misericórdia de Porto Alegre
Recruiting
Hospital Sao Lucas
Recruiting
Instituto D'or de Pesquisa e Ensino - Rio de Janeiro
Recruiting
Hospital Santa Izabel - Santa Casa de Misericórdia da Bahia
Recruiting
Hospital Samaritano de São Paulo
Recruiting
Instituto D'Or de Pesquisa e Ensino - Sao Paulo
Recruiting
StudyCELESTIAL-RRCLL
SponsorBeiGene
Study typeInterventional
Conditions
Chronic lymphocytic leukemia
Requirements
From 18 YearsAll Gender
Unique study IDclinicaltrials.gov
NCT06943872
